@article{oai:nagasaki-u.repo.nii.ac.jp:00011150,
 author = {Tashiro, Masato and Izumikawa, Koichi and Minematsu, Asuka and Hirano, Katsuji and Iwanaga, Naoki and Ide, Shotaro and Mihara, Tomo and Hosogaya, Naoki and Takazono, Takahiro and Morinaga, Yoshitomo and Nakamura, Shigeki and Kurihara, Shintaro and Imamura, Yoshifumi and Miyazaki, Taiga and Nishino, Tomoya and Tsukamoto, Misuzu and Kakeya, Hiroshi and Yamamoto, Yoshihiro and Yanagihara, Yoshihiro and Yasuoka, Akira and Tashiro, Takayoshi and Kohno, Shigeru},
 issue = {1},
 journal = {Antimicrobial Agents and Chemotherapy},
 month = {Jan},
 note = {We investigated the triazole, amphotericin B, and micafungin susceptibilities of 196 A. fumigatus clinical isolates in Nagasaki, Japan. The percentages of non-wild-type (non-WT) isolates for which MICs of itraconazole, posaconazole, and voriconazole were above the ECV were 7.1%, 2.6%, and 4.1%, respectively. A G54 mutation in cyp51A was detected in 64.2% (9/14 isolates) and 100% (5/5 isolates) of non-WT isolates for itraconazole and posaconazole, respectively. Amphotericin B MICs of ≥2 μg/ml and micafungin minimum effective concentrations (MECs) of ≥16 μg/ml were recorded for two and one isolates, respectively., Antimicrobial Agents and Chemotherapy, 56(1), pp.584-587; 2012},
 pages = {584--587},
 title = {Antifungal Susceptibilities of Aspergillus fumigatus Clinical Isolates Obtained in Nagasaki, Japan},
 volume = {56},
 year = {2012}
}